Orelabrutinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Orelabrutinib 是一种口服活性且不可逆的布鲁顿酪氨酸激酶 (BTK) 抑制剂。

Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). (In Vitro):With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.(In Vivo):Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.

Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

ICP-022

Tyrosine Kinase

BTK

BTK

——

——

1655504-04-3

427.5

C26H25N3O3

>98% (HPLC)

DMSO:250 mg/mL (584.80 mM; Need ultrasonic)

NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C

——

(-20℃)

With Ice Pack

≥ 2 years